Wednesday, May 30, 2012
Cell Therapeutics Inc., of Seattle, said it will sell $40 million of shares of Series 15 convertible preferred stock and warrants to purchase shares of common stock in a registered direct offering to an institutional investor in two tranches of $20 million each.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.